Bill

Bill > HR153


US HR153

US HR153
Protecting Consumer Access to Generic Drugs Act of 2021


summary

Introduced
01/04/2021
In Committee
03/04/2021
Crossed Over
Passed
Dead
01/03/2023

Introduced Session

117th Congress

Bill Summary

A BILL To prohibit brand name drug manufacturers from compen- sating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit bio- logical product manufacturers from compensating bio- similar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.

AI Summary

This bill prohibits brand name drug and biological product manufacturers from compensating generic drug and biosimilar manufacturers to delay the entry of their competing products into the market. The bill gives the Federal Trade Commission the authority to enforce these prohibitions as unfair or deceptive acts or practices and to seek civil penalties for violations. The bill also requires certification of any agreements between brand name and generic or biosimilar manufacturers, and allows the 180-day exclusivity period for generic drugs to be forfeited if the agreement violates the bill's provisions.

Committee Categories

Business and Industry, Government Affairs, Health and Social Services

Sponsors (19)

Last Action

Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. (on 03/04/2021)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...